Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Time to Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw strong trading volume on Monday. Approximately 2,856,577 shares were traded during trading, an increase of 196% from the previous session’s volume of 966,662 shares. The stock last traded at $2.9650 and had previously closed at $2.94.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IVA. Truist Financial boosted their target price on Inventiva from $13.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Guggenheim raised their price objective on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Cantor Fitzgerald began coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Weiss Ratings downgraded Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.86.

Inventiva Stock Performance

The firm has a 50 day moving average price of $4.04 and a 200 day moving average price of $4.46.

Inventiva (NASDAQ:IVA) last posted its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million for the quarter. As a group, analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Platt Investment Counsel LLC purchased a new stake in shares of Inventiva during the 3rd quarter worth $45,000. Engineers Gate Manager LP raised its holdings in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares in the last quarter. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Inventiva in the 1st quarter valued at about $1,111,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.